• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Understanding cytokine release syndrome.

作者信息

Gödel Philipp, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael

机构信息

Intensive Care Unit and Interventional Immunology Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany.

出版信息

Intensive Care Med. 2018 Mar;44(3):371-373. doi: 10.1007/s00134-017-4943-5. Epub 2017 Sep 27.

DOI:10.1007/s00134-017-4943-5
PMID:28956093
Abstract
摘要

相似文献

1
Understanding cytokine release syndrome.了解细胞因子释放综合征。
Intensive Care Med. 2018 Mar;44(3):371-373. doi: 10.1007/s00134-017-4943-5. Epub 2017 Sep 27.
2
How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response.体外试验对体内细胞因子释放综合征的预测能力如何？方法比较揭示了敏感性和反应频率方面令人担忧的差异。
Cytokine. 2013 Oct;64(1):471-2. doi: 10.1016/j.cyto.2013.07.009. Epub 2013 Jul 30.
3
Response to the letter to the editor by Susan Thorpe et al.: how predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response.对苏珊·索普等人致编辑信的回应：体外试验对体内细胞因子释放综合征的预测性如何？方法比较揭示了敏感性和反应频率方面令人担忧的差异。
Cytokine. 2013 Oct;64(1):473-5; discussion 476. doi: 10.1016/j.cyto.2013.07.014. Epub 2013 Aug 3.
4
A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.一种全血体外细胞因子释放试验，采用水性单克隆抗体呈递方法，用于预测人类治疗性蛋白引起的细胞因子释放综合征。
Cytokine. 2012 Dec;60(3):828-37. doi: 10.1016/j.cyto.2012.08.018. Epub 2012 Sep 15.
5
Cytokine release syndrome: Who is at risk and how to treat.细胞因子释放综合征：哪些人有风险以及如何治疗。
Best Pract Res Clin Haematol. 2017 Dec;30(4):336-340. doi: 10.1016/j.beha.2017.09.002. Epub 2017 Sep 22.
6
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.急性淋巴细胞白血病嵌合抗原受体T细胞治疗后细胞因子释放综合征预测生物标志物的鉴定
Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.
7
Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.在接受帕博利珠单抗治疗的转移性肺癌患者中出现提示细胞因子释放综合征的弥漫性水肿。
Immunotherapy. 2017 Mar;9(4):309-311. doi: 10.2217/imt-2016-0134.
8
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.黑色素瘤序贯免疫治疗导致的非典型严重免疫相关不良反应。
Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.
9
Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.开发一种人类全血检测方法，通过多重细胞因子分析和层次聚类分析，预测与抗 CD28 超激动剂相似的细胞因子释放。
Int Immunopharmacol. 2011 Nov;11(11):1697-705. doi: 10.1016/j.intimp.2011.06.001. Epub 2011 Jun 29.
10
Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.用于治疗恶性胶质瘤的被动抗体介导免疫疗法。
Neurosurg Clin N Am. 2010 Jan;21(1):67-76. doi: 10.1016/j.nec.2009.08.010.

引用本文的文献

1
Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的非小细胞肺癌患者免疫介导性肝损伤的临床特征及危险因素
Front Oncol. 2025 Aug 13;15:1575376. doi: 10.3389/fonc.2025.1575376. eCollection 2025.
2
Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report.帕博利珠单抗诱导的同时性难治性系统性毛细血管渗漏和细胞因子释放综合征：一例报告
Curr Oncol. 2025 Aug 18;32(8):469. doi: 10.3390/curroncol32080469.
3
Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications.

本文引用的文献

1
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病后的细胞因子释放综合征
Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.
2
Immunotherapeutic implications of IL-6 blockade for cytokine storm.白细胞介素-6阻断对细胞因子风暴的免疫治疗意义。
Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020.
3
Critical care of patients with cancer.癌症患者的重症监护
多发性骨髓瘤中与替西妥单抗相关的细胞因子释放综合征：基于病例的机制、管理及临床意义文献综述
Arch Clin Cases. 2025 Jul 15;12(2):98-101. doi: 10.22551/2025.47.1202.10320. eCollection 2025.
4
Deep insight into cytokine storm: from pathogenesis to treatment.深入洞察细胞因子风暴：从发病机制到治疗。
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
5
Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.一名银屑病患者接受抗程序性死亡-1治疗引发的细胞因子释放综合征：免疫检查点抑制剂的阴暗面
World J Clin Cases. 2024 Dec 16;12(35):6782-6790. doi: 10.12998/wjcc.v12.i35.6782.
6
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.案例报告：在与派姆单抗联合使用时，PD-L1 依赖性 CD28 共刺激剂和双重 PD-L1/CTLA-4 检查点抑制剂达沃西妥单抗（ALPN-202）治疗后发生致命性免疫介导性心肌炎。
J Immunother Cancer. 2024 Aug 13;12(8):e009475. doi: 10.1136/jitc-2024-009475.
7
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.托珠单抗在新辅助免疫化疗诱导的细胞因子释放综合征患者中的成功应用。
Cancer Rep (Hoboken). 2024 Jul;7(7):e2145. doi: 10.1002/cnr2.2145.
8
Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.托珠单抗和细胞因子吸附剂用于治疗伊匹单抗联合纳武利尤单抗免疫治疗后迟发性严重细胞因子释放综合征。
Immunotherapy. 2024;16(12):791-801. doi: 10.1080/1750743X.2024.2370180. Epub 2024 Jul 17.
9
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.CD19 靶向 CAR-T 细胞疗法治疗 B 细胞恶性肿瘤后发热患者早期感染的快速识别。
J Transl Med. 2024 Jul 2;22(1):613. doi: 10.1186/s12967-024-05308-2.
10
Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes.嵌合抗原受体T细胞疗法后的急性肾损伤：探索临床模式、管理及结局
Clin Kidney J. 2024 May 30;17(6):sfae123. doi: 10.1093/ckj/sfae123. eCollection 2024 Jun.
CA Cancer J Clin. 2016 Nov 12;66(6):496-517. doi: 10.3322/caac.21351. Epub 2016 Jun 27.
4
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.用于血液系统恶性肿瘤的靶向CD19嵌合抗原受体T细胞疗法：解读迄今为止的临床结果
Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20.
5
Toxicities of chimeric antigen receptor T cells: recognition and management.嵌合抗原受体T细胞的毒性：识别与管理
Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.
6
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.成年B细胞急性淋巴细胞白血病患者中具有特定CD4+:CD8+组成的CD19嵌合抗原受体T细胞。
J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.
7
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.急性淋巴细胞白血病嵌合抗原受体T细胞治疗后细胞因子释放综合征预测生物标志物的鉴定
Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.
8
Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.一例复发系统性间变性大细胞淋巴瘤（sALCL）患者首次使用维布妥昔单抗后发生严重细胞因子释放综合征：病例报告及文献复习
Eur J Haematol. 2015 Jun;94(6):554-7. doi: 10.1111/ejh.12396. Epub 2014 Jul 2.
9
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
10
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.